8-K: Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides Business Update

Aptevo Therapeutics announced its first quarter 2024 financial results, highlighting progress in clinical programs and a stable disease outcome for a breast cancer patient in the ALG.APV-527 trial.

Summary

• Aptevo Therapeutics reported a net loss of $6.8 million for the first quarter of 2024, compared to a net income of $2.8 million for the same period in 2023.
• The company's cash and cash equivalents totaled $10.3 million as of March 31, 2024, which increases to $14.3 million on a proforma basis including proceeds from an equity raise closed on April 10, 2024.
• Research and development expenses decreased to $3.8 million in Q1 2024 from $4.2 million in Q1 2023, primarily due to lower spending on the APVO436 clinical trial and preclinical projects.
• General and administrative expenses also decreased to $3.2 million in Q1 2024 from $3.6 million in Q1 2023, mainly due to lower employee and consulting costs.
• A heavily pre-treated breast cancer patient in the ALG.APV-527 trial achieved stable disease for over eleven months and was successfully transitioned to a higher dose with no new adverse events.
• Aptevo is on track to initiate a dose optimization trial for APVO436 in frontline AML in the second quarter of 2024.
• The ALG.APV-527 trial is more than 50% enrolled and is currently dosing cohort 5.
• The company's APVO436 Phase 1b trial showed a 91% clinical benefit rate in combination with venetoclax + azacitidine in venetoclax naive patients.

Sentiment

Score: 6

Explanation: The document presents mixed signals. While there is positive clinical progress and cost reductions, the significant net loss and decreased cash position temper the overall sentiment. The company is making progress but faces financial challenges.

Positives

• A heavily pre-treated breast cancer patient in the ALG.APV-527 trial experienced long-lasting stable disease and was successfully transitioned to a higher dose with no new adverse events.
• The company is on track to initiate the APVO436 dose optimization trial in frontline AML in the second quarter of 2024.
• The APVO436 Phase 1b trial demonstrated a 91% clinical benefit rate in combination with venetoclax + azacitidine in venetoclax naive patients.
• The company has partnered with Prometrika for the upcoming APVO436 study.
• The company has seen a decrease in both research and development and general and administrative expenses.
• The ALG.APV-527 trial has shown measurable drug levels in circulation and reproducible elevation of serum pharmacodynamic markers.

Negatives

• Aptevo reported a net loss of $6.8 million for the first quarter of 2024, a significant decrease from the net income of $2.8 million in the same period of 2023.
• The company's cash position decreased from $16.9 million at the end of 2023 to $10.3 million as of March 31, 2024, although this was partially offset by a subsequent equity raise.

Risks

• The company's financial results show a significant net loss for the quarter, indicating potential financial challenges.
• Clinical trial results may vary from preliminary assessments, and there are risks associated with the development of novel therapies.
• The company faces risks related to regulatory approvals, competitive products, and the ability to raise funds or enter into strategic partnerships.
• Macroeconomic conditions, geopolitical risks, and public health crises could impact the company's business.

Future Outlook

Aptevo plans to initiate a dose optimization trial for APVO436 in frontline AML in the second quarter of 2024 and continues to evaluate ALG.APV-527 in multiple solid tumor types. The company is optimistic about the potential of its clinical programs and the performance of its molecules.

Management Comments

• We are particularly enthusiastic about one breast cancer patient in our ALG.APV-527 trial who has remained on study with stable disease for more than eleven months, in addition, to being safely and successfully transitioned to a higher dose level within the study.
• This rarely happens in an early-stage trial, and we believe it underscores the potential of our bispecific solid tumor candidate.
• Additionally, we plan to initiate our APVO436 dose optimization trial in frontline AML patients this quarter.
• Overall, we are excitingly seeing in the clinic that our molecules are performing as they were engineered to perform.

Industry Context

Aptevo is operating in the competitive immuno-oncology space, focusing on novel therapies for cancer treatment. The company's ADAPTIR and ADAPTIR-FLEX platforms are designed to improve treatment outcomes for cancer patients. The progress in clinical trials and the stable disease outcome in a breast cancer patient are positive signs in this context.

Comparison to Industry Standards

• The 91% clinical benefit rate for APVO436 in combination with venetoclax + azacitidine in venetoclax naive AML patients is a strong result compared to standard AML treatments.
• The stable disease outcome for a heavily pre-treated breast cancer patient in the ALG.APV-527 trial for over eleven months is notable, as many early-stage trials do not see such prolonged responses.
• Competitors in the bispecific antibody space include companies like Amgen and Regeneron, who have also seen success in this area, but Aptevo's unique approach with its ADAPTIR platform may offer a competitive advantage.
• The company's focus on reducing the likelihood and severity of CRS with APVO436 is a key differentiator compared to other CD3-targeting therapies.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the clinical progress.
• Employees may be affected by cost-cutting measures, but the company's progress in clinical trials could be motivating.
• Patients may benefit from the development of new cancer therapies.
• Creditors may be concerned about the company's financial performance.

Next Steps

• Aptevo plans to initiate a dose optimization trial for APVO436 in frontline AML in the second quarter of 2024.
• The company will continue to evaluate ALG.APV-527 in multiple solid tumor types.
• The company will continue dose escalation in higher-dose cohorts for ALG.APV-527.

Key Dates

Keywords

Aptevo Therapeutics, Immuno-oncology, ADAPTIR, ADAPTIR-FLEX, ALG.APV-527, APVO436, AML, Clinical Trial, Bispecific Antibody, Cancer Therapy